$BMRN
BIOMARIN PHARMACEUTICAL INC

2013 Q4 Form 10-Q Financial Statement

#000119312513413125 Filed on October 28, 2013

View on sec.gov

Income Statement

Concept 2013 Q4 2013 Q3 2012 Q3
Revenue $146.9M $136.9M $128.1M
YoY Change 11.37% 6.84% 12.95%
Cost Of Revenue $24.60M $28.05M $24.62M
YoY Change -7.17% 13.95% 9.69%
Gross Profit $122.3M $108.8M $103.5M
YoY Change 16.03% 5.14% 13.76%
Gross Profit Margin 83.25% 79.5% 80.78%
Selling, General & Admin $71.00M $61.84M $46.34M
YoY Change 29.09% 33.46% 3.25%
% of Gross Profit 58.05% 56.83% 44.77%
Research & Development $97.30M $88.06M $66.21M
YoY Change 15.28% 33.01% 13.03%
% of Gross Profit 79.56% 80.93% 63.97%
Depreciation & Amortization -$1.500M $9.200M $8.900M
YoY Change -113.76% 3.37% 9.88%
% of Gross Profit -1.23% 8.45% 8.6%
Operating Expenses $180.4M $149.9M $112.5M
YoY Change 29.41% 33.19% 8.79%
Operating Profit -$58.10M -$50.72M -$10.49M
YoY Change 70.88% 383.5% -32.39%
Interest Expense $1.200M $526.0K $1.837M
YoY Change -108.39% -71.37% -15.27%
% of Operating Profit
Other Income/Expense, Net $600.0K $200.0K $100.0K
YoY Change -133.33% 100.0% -133.33%
Pretax Income -$59.40M -$52.32M -$11.76M
YoY Change 18.56% 344.83% -40.39%
Income Tax $2.600M $704.0K -$6.404M
% Of Pretax Income
Net Earnings -$62.00M -$53.02M -$5.357M
YoY Change 16.98% 889.73% -69.65%
Net Earnings / Revenue -42.21% -38.74% -4.18%
Basic Earnings Per Share -$0.38
Diluted Earnings Per Share -$434.5K -$0.38 -$43.76K
COMMON SHARES
Basic Shares Outstanding 142.2M shares 140.8M shares 123.6M shares
Diluted Shares Outstanding 140.8M shares

Balance Sheet

Concept 2013 Q4 2013 Q3 2012 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $784.7M $379.7M $426.5M
YoY Change 75.23% -10.97% 90.06%
Cash & Equivalents $568.8M $181.6M $181.3M
Short-Term Investments $215.9M $198.1M $245.1M
Other Short-Term Assets $41.71M $28.16M $54.82M
YoY Change 63.5% -48.63% 67.63%
Inventory $162.6M $148.7M $120.8M
Prepaid Expenses $21.14M $11.42M
Receivables $117.8M $124.7M $117.3M
Other Receivables $0.00 $0.00 $9.000M
Total Short-Term Assets $1.137B $713.5M $719.4M
YoY Change 53.0% -0.82% 47.72%
LONG-TERM ASSETS
Property, Plant & Equipment $319.3M $285.7M $273.7M
YoY Change 12.25% 4.36% 2.83%
Goodwill $54.26M $54.26M $51.54M
YoY Change 5.27% 5.27%
Intangibles $163.1M $165.8M $165.6M
YoY Change 0.1% 0.1%
Long-Term Investments $268.5M $148.6M $107.6M
YoY Change 129.29% 38.1% -26.7%
Other Assets $156.2M $14.01M $19.74M
YoY Change 699.07% -29.02% -91.87%
Total Long-Term Assets $1.107B $907.1M $848.0M
YoY Change 34.15% 6.96% 4.94%
TOTAL ASSETS
Total Short-Term Assets $1.137B $713.5M $719.4M
Total Long-Term Assets $1.107B $907.1M $848.0M
Total Assets $2.244B $1.621B $1.567B
YoY Change 43.08% 3.39% 21.02%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $36.89M $15.63M $11.46M
YoY Change 53.77% 36.42% 61.39%
Accrued Expenses $58.41M $58.67M $36.39M
YoY Change 35.34% 61.24% -43.5%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $23.40M
YoY Change -100.0% -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $183.3M $167.6M $134.9M
YoY Change 7.53% 24.24% 61.98%
LONG-TERM LIABILITIES
Long-Term Debt $655.6M $78.30M $324.9M
YoY Change 101.79% -75.9% -6.72%
Other Long-Term Liabilities $33.39M $34.41M $92.39M
YoY Change 25.19% -62.76% 76.32%
Total Long-Term Liabilities $33.39M $34.41M $92.39M
YoY Change 25.19% -62.76% -76.94%
TOTAL LIABILITIES
Total Short-Term Liabilities $183.3M $167.6M $134.9M
Total Long-Term Liabilities $33.39M $34.41M $92.39M
Total Liabilities $903.0M $344.0M $552.2M
YoY Change 63.42% -37.69% 6.09%
SHAREHOLDERS EQUITY
Retained Earnings -$715.8M -$653.8M -$486.4M
YoY Change 32.69% 34.41%
Common Stock $2.059B $1.926B $1.506B
YoY Change 31.83% 27.92%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.341B $1.276B $1.015B
YoY Change
Total Liabilities & Shareholders Equity $2.244B $1.621B $1.567B
YoY Change 43.08% 3.39% 21.02%

Cashflow Statement

Concept 2013 Q4 2013 Q3 2012 Q3
OPERATING ACTIVITIES
Net Income -$62.00M -$53.02M -$5.357M
YoY Change 16.98% 889.73% -69.65%
Depreciation, Depletion And Amortization -$1.500M $9.200M $8.900M
YoY Change -113.76% 3.37% 9.88%
Cash From Operating Activities -$9.000M -$9.500M $14.20M
YoY Change -175.0% -166.9% 61.36%
INVESTING ACTIVITIES
Capital Expenditures -$29.80M -$13.20M -$15.00M
YoY Change 114.39% -12.0% -73.36%
Acquisitions
YoY Change
Other Investing Activities -$276.8M $16.50M -$5.900M
YoY Change 618.96% -379.66% 210.53%
Cash From Investing Activities -$306.5M $3.300M -$21.00M
YoY Change 486.04% -115.71% -63.98%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 705.0M 12.30M 10.30M
YoY Change 1680.3% 19.42% 32.05%
NET CHANGE
Cash From Operating Activities -9.000M -9.500M 14.20M
Cash From Investing Activities -306.5M 3.300M -21.00M
Cash From Financing Activities 705.0M 12.30M 10.30M
Net Change In Cash 389.5M 6.100M 3.500M
YoY Change -55742.86% 74.29% -108.39%
FREE CASH FLOW
Cash From Operating Activities -$9.000M -$9.500M $14.20M
Capital Expenditures -$29.80M -$13.20M -$15.00M
Free Cash Flow $20.80M $3.700M $29.20M
YoY Change -19.69% -87.33% -55.15%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2012Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
181330000
CY2013Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
142200995 shares
CY2013Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2013Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
142200995 shares
CY2013Q3 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
5392000
CY2013Q3 us-gaap Convertible Debt
ConvertibleDebt
78310000
CY2013Q3 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
4240000
CY2013Q3 us-gaap Asset Retirement Obligation
AssetRetirementObligation
4000000
CY2013Q3 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
76378000
CY2013Q3 us-gaap Liabilities Current
LiabilitiesCurrent
167633000
CY2013Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
11473000
CY2013Q3 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
78310000
CY2013Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
28574000
CY2013Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
176443000
CY2013Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1891000
CY2013Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
15632000
CY2013Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
34411000
CY2013Q3 us-gaap Stockholders Equity
StockholdersEquity
1276486000
CY2013Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1926133000
CY2013Q3 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
5279000
CY2013Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
167633000
CY2013Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-653811000
CY2013Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
58666000
CY2013Q3 us-gaap Deferred Compensation Cash Based Arrangements Liability Current
DeferredCompensationCashBasedArrangementsLiabilityCurrent
1559000
CY2013Q3 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
0
CY2013Q3 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
10147000
CY2013Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
376000
CY2013Q3 us-gaap Accrued Vacation Current
AccruedVacationCurrent
9717000
CY2013Q3 us-gaap Liabilities
Liabilities
344044000
CY2013Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
26881000
CY2013Q3 us-gaap Common Stock Value
CommonStockValue
142000
CY2013Q3 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
280387000
CY2013Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1620530000
CY2013Q3 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
37190000
CY2013Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
14010000
CY2013Q3 us-gaap Other Assets Fair Value Disclosure
OtherAssetsFairValueDisclosure
4839000
CY2013Q3 us-gaap Land
Land
11608000
CY2013Q3 us-gaap Goodwill
Goodwill
54258000
CY2013Q3 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
328430000
CY2013Q3 us-gaap Common Stock Issued Employee Stock Trust
CommonStockIssuedEmployeeStockTrust
7451000
CY2013Q3 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
67083000
CY2013Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
165791000
CY2013Q3 us-gaap Financing Receivable Recorded Investment Past Due
FinancingReceivableRecordedInvestmentPastDue
5229000
CY2013Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
124745000
CY2013Q3 us-gaap Inventory Net
InventoryNet
148684000
CY2013Q3 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
74430000
CY2013Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
52338000
CY2013Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
462107000
CY2013Q3 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
32238000
CY2013Q3 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
88865000
CY2013Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
15350000
CY2013Q3 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
854000
CY2013Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
285664000
CY2013Q3 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
238703000
CY2013Q3 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
181565000
CY2013Q3 us-gaap Assets
Assets
1620530000
CY2013Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
534838000
CY2013Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
181565000
CY2013Q3 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
12152000
CY2013Q3 us-gaap Short Term Investments
ShortTermInvestments
198086000
CY2013Q3 us-gaap Buildings And Improvements Gross
BuildingsAndImprovementsGross
154479000
CY2013Q3 us-gaap Other Assets Current
OtherAssetsCurrent
28161000
CY2013Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
80996000
CY2013Q3 us-gaap Construction In Progress Gross
ConstructionInProgressGross
64756000
CY2013Q3 us-gaap Available For Sale Securities
AvailableForSaleSecurities
345857000
CY2013Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
118242000
CY2013Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
198086000
CY2013Q3 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
192672000
CY2013Q3 us-gaap Long Term Investments
LongTermInvestments
147771000
CY2013Q3 us-gaap Available For Sale Securities Debt Maturities Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAmortizedCost
345857000
CY2013Q3 us-gaap Assets Current
AssetsCurrent
713479000
CY2013Q3 bmrn Computer Hardware And Software
ComputerHardwareAndSoftware
63164000
CY2013Q3 bmrn Other Liabilities Noncurrent Fair Value Disclosure
OtherLiabilitiesNoncurrentFairValueDisclosure
46463000
CY2013Q3 bmrn Available For Sale Securities Debt Maturities After One Through Two Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue
147771000
CY2013Q3 bmrn Contingent And Deferred Acquisition Payments
ContingentAndDeferredAcquisitionPayments
26500000
CY2013Q3 bmrn Other Liabilities Current Fair Value Disclosure
OtherLiabilitiesCurrentFairValueDisclosure
29915000
CY2013Q3 bmrn Other Assets Current Fair Value Disclosure
OtherAssetsCurrentFairValueDisclosure
2577000
CY2013Q3 bmrn Business Combination Contingent Consideration At Fair Value Current
BusinessCombinationContingentConsiderationAtFairValueCurrent
26536000
CY2013Q3 bmrn Available For Sale Securities Gross Unrealized Gain Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments
17683000
CY2013Q3 bmrn Available For Sale Securities Gross Unrealized Loss Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments
256000
CY2013Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
142212657 shares
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
46272000
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
125809162 shares
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
125809162 shares
CY2012Q4 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
3915000
CY2012Q4 us-gaap Convertible Debt
ConvertibleDebt
348224000
CY2012Q4 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
2072000
CY2012Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
62613000
CY2012Q4 us-gaap Asset Retirement Obligation
AssetRetirementObligation
3900000
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
170433000
CY2012Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-202000
CY2012Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
324859000
CY2012Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
27530000
CY2012Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
149122000
CY2012Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
6179000
CY2012Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
23993000
CY2012Q4 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
63689000
CY2012Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
45309000
CY2012Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
433595000
CY2012Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
26674000
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
1015763000
CY2012Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1561890000
CY2012Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
4991000
CY2012Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
147068000
CY2012Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-539448000
CY2012Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
43156000
CY2012Q4 us-gaap Deferred Compensation Cash Based Arrangements Liability Current
DeferredCompensationCashBasedArrangementsLiabilityCurrent
6440000
CY2012Q4 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
23365000
CY2012Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
9625000
CY2012Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
348000
CY2012Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
8403000
CY2012Q4 us-gaap Liabilities
Liabilities
585880000
CY2012Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
18951000
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
126000
CY2012Q4 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
811798000
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1601643000
CY2012Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
33296000
CY2012Q4 us-gaap Asset Retirement Obligation Current
AssetRetirementObligationCurrent
1685000
CY2012Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
16611000
CY2012Q4 us-gaap Other Assets Fair Value Disclosure
OtherAssetsFairValueDisclosure
5867000
CY2012Q4 us-gaap Land
Land
11608000
CY2012Q4 us-gaap Goodwill
Goodwill
51543000
CY2012Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
386010000
CY2012Q4 us-gaap Common Stock Issued Employee Stock Trust
CommonStockIssuedEmployeeStockTrust
6603000
CY2012Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
65918000
CY2012Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
162980000
CY2012Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
109066000
CY2012Q4 us-gaap Inventory Net
InventoryNet
128695000
CY2012Q4 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
29454000
CY2012Q4 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
79915000
CY2012Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
11943000
CY2012Q4 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
1080000
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
284473000
CY2012Q4 us-gaap Deferred Tax Assets Net Noncurrent
DeferredTaxAssetsNetNoncurrent
225501000
CY2012Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
180527000
CY2012Q4 us-gaap Assets
Assets
1601643000
CY2012Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
578440000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
180527000
CY2012Q4 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
11143000
CY2012Q4 us-gaap Short Term Investments
ShortTermInvestments
270211000
CY2012Q4 us-gaap Buildings And Improvements Gross
BuildingsAndImprovementsGross
144700000
CY2012Q4 us-gaap Other Assets Current
OtherAssetsCurrent
25509000
CY2012Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
71443000
CY2012Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
64300000
CY2012Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
386204000
CY2012Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
118242000
CY2012Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
270211000
CY2012Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
181931000
CY2012Q4 us-gaap Long Term Investments
LongTermInvestments
115993000
CY2012Q4 us-gaap Available For Sale Securities Debt Maturities Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAmortizedCost
386204000
CY2012Q4 us-gaap Assets Current
AssetsCurrent
743462000
CY2012Q4 bmrn Computer Hardware And Software
ComputerHardwareAndSoftware
56011000
CY2012Q4 bmrn Other Liabilities Noncurrent Fair Value Disclosure
OtherLiabilitiesNoncurrentFairValueDisclosure
42646000
CY2012Q4 bmrn Available For Sale Securities Debt Maturities After One Through Two Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue
115993000
CY2012Q4 bmrn Contingent And Deferred Acquisition Payments
ContingentAndDeferredAcquisitionPayments
30618000
CY2012Q4 bmrn Other Liabilities Current Fair Value Disclosure
OtherLiabilitiesCurrentFairValueDisclosure
19967000
CY2012Q4 bmrn Other Assets Current Fair Value Disclosure
OtherAssetsCurrentFairValueDisclosure
5842000
CY2012Q4 bmrn Business Combination Contingent Consideration At Fair Value Current
BusinessCombinationContingentConsiderationAtFairValueCurrent
10764000
CY2012Q4 bmrn Available For Sale Securities Gross Unrealized Gain Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedGainAccumulatedInInvestments
473000
CY2012Q4 bmrn Available For Sale Securities Gross Unrealized Loss Accumulated In Investments
AvailableForSaleSecuritiesGrossUnrealizedLossAccumulatedInInvestments
279000
dei Trading Symbol
TradingSymbol
BMRN
dei Entity Registrant Name
EntityRegistrantName
BIOMARIN PHARMACEUTICAL INC
dei Amendment Flag
AmendmentFlag
false
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2013-09-30
dei Entity Central Index Key
EntityCentralIndexKey
0001048477
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
us-gaap Basis Of Accounting
BasisOfAccounting
<div> <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>(2) BASIS OF PRESENTATION</b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The accompanying Condensed Consolidated Financial Statements have been prepared pursuant to the rules and regulations of the SEC for Quarterly Reports on Form 10-Q and do not include all of the information and note disclosures required by U.S. generally accepted accounting principles (U.S. GAAP) for complete financial statements. The Condensed Consolidated Financial Statements should therefore be read in conjunction with the Consolidated Financial Statements and Notes thereto for the fiscal year ended December&#xA0;31, 2012 included in the Company&#x2019;s Annual Report on Form 10-K.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The accompanying Condensed Consolidated Financial Statements have been prepared in accordance with U.S. GAAP, which requires management to make estimates and assumptions that affect amounts reported in the Condensed Consolidated Financial Statements and accompanying disclosures. Although these estimates are based on management&#x2019;s best knowledge of current events and actions that the Company may undertake in the future, actual results may be different from those estimates. The Condensed Consolidated Financial Statements reflect all adjustments of a normal, recurring nature that are, in the opinion of management, necessary for a fair presentation of results for these interim periods. The results of operations for the three and nine months ended September&#xA0;30, 2013 are not necessarily indicative of the results that may be expected for the fiscal year ending December&#xA0;31, 2013.</font></p> <p style="MARGIN-TOP: 12px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">The Company has evaluated events and transactions subsequent to the balance sheet date. Based on this evaluation, the Company is not aware of any events or transactions that occurred subsequent to the balance sheet date but prior to filing this Quarterly Report on Form 10-Q that would require recognition or disclosure in the Condensed Consolidated Financial Statements, except for the transaction in Note 20.</font></p> </div>
us-gaap Nature Of Operations
NatureOfOperations
<div> <p style="margin-top:12px;margin-bottom:0px"><font style="font-family:Times New Roman" size="2"><b>(1) NATURE OF OPERATIONS AND BUSINESS RISKS</b></font></p> <p style="margin-top:6px;margin-bottom:0px; text-indent:4%"> <font style="font-family:Times New Roman" size="2">BioMarin Pharmaceutical Inc. (the Company or BioMarin), a Delaware corporation, develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. BioMarin selects product candidates for diseases and conditions that represent a significant unmet medical need, have well-understood biology and provide an opportunity to be first-to-market or offer a significant benefit over existing products. The Company&#x2019;s product portfolio is comprised of four approved products and multiple investigational product candidates. The Company&#x2019;s approved products are Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Firdapse (amifampridine phosphate) and Aldurazyme (laronidase).</font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"> <font style="font-family:Times New Roman" size="2">Through September&#xA0;30, 2013, the Company had accumulated losses of approximately $653.8 million. Management believes that the Company&#x2019;s cash, cash equivalents, short-term and long-term investments at September&#xA0;30, 2013 and the proceeds from the convertible notes offering in October 2013 as discussed in Note 20, will be sufficient to meet the Company&#x2019;s obligations for at least the next twelve months based on management&#x2019;s current business plans. If the Company elects to increase its spending on development programs significantly above current long-term plans or enters into potential licenses and other acquisitions of complementary technologies, products or companies, the Company may need additional capital. The Company expects to continue to finance future cash needs that exceed its operating activities primarily through its current cash, cash equivalents, short-term and long-term investments, and to the extent necessary, through proceeds from equity or debt financings, loans and collaborative agreements with corporate partners.</font></p> <p style="margin-top:12px;margin-bottom:0px; text-indent:4%"> <font style="font-family:Times New Roman" size="2">The Company is subject to a number of risks, including: the financial performance of Naglazyme, Kuvan, Firdapse and Aldurazyme; the potential need for additional financings; its ability to successfully commercialize its product candidates, if approved; the uncertainty of the Company&#x2019;s research and development efforts resulting in future successful commercial products; obtaining regulatory approval for new products; significant competition from larger organizations; reliance on the proprietary technology of others; dependence on key personnel; uncertain patent protection; dependence on corporate partners and collaborators; and possible restrictions on reimbursement from governmental agencies and healthcare organizations, as well as other changes in the health care industry.</font></p> </div>
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
2403722 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
136102000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
30.62
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-48338000
us-gaap Description Of New Accounting Pronouncements Not Yet Adopted
DescriptionOfNewAccountingPronouncementsNotYetAdopted
<div> <p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"><font style="FONT-FAMILY: Times New Roman" size="2"><b>(4) RECENT ACCOUNTING PRONOUNCEMENTS</b></font></p> <p style="MARGIN-TOP: 6px; TEXT-INDENT: 4%; MARGIN-BOTTOM: 0px"> <font style="FONT-FAMILY: Times New Roman" size="2">Except for Financial Accounting Standards Board (FASB) Accounting Standards Update 2013-02 (ASU 2013-02), <i>Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income,</i> there have been no new accounting pronouncements or changes to accounting pronouncements during the period ended September&#xA0;30, 2013, as compared to the recent accounting pronouncements described in the Company&#x2019;s Annual Report on Form 10-K for the year-ended December&#xA0;31, 2012, that are of significance or potential significance to the Company. ASU 2013-02 requires an entity to present either on the face of the financial statements where income is presented or in the notes to the financial statements, significant amounts reclassified out of accumulated other comprehensive income by the respective line items of net income. See Note 17 to these Condensed Consolidated Financial Statements for the expanded disclosures required by ASU 2013-02.</font></p> </div>
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
18923000 shares
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.84
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-711000
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
12152000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
35440000
us-gaap Income Taxes Paid
IncomeTaxesPaid
13165000
us-gaap Investment Income Interest
InvestmentIncomeInterest
1942000
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
394074000
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
344000
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
9875000
us-gaap Excess Tax Benefit From Share Based Compensation Operating Activities
ExcessTaxBenefitFromShareBasedCompensationOperatingActivities
335000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
1776000
us-gaap Payments To Acquire Interest In Joint Venture
PaymentsToAcquireInterestInJointVenture
485000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
179192000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
1692000
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-117128000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
15679000
us-gaap Maturities Of Subordinated Debt
MaturitiesOfSubordinatedDebt
98000
us-gaap Derivative Instruments Gain Loss Recognized In Other Comprehensive Income Effective Portion Net
DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet
-2100000
us-gaap Interest Paid Net
InterestPaidNet
3238000
us-gaap Revenues
Revenues
401612000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-102688000
us-gaap Contracts Revenue
ContractsRevenue
2778000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
307000
us-gaap Operating Income Loss
OperatingIncomeLoss
-103697000
us-gaap Royalty Revenue
RoyaltyRevenue
4760000
us-gaap Other Comprehensive Income Loss Before Reclassifications Net Of Tax
OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
12294000
us-gaap Net Income Loss
NetIncomeLoss
-114363000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-4149000
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
430000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
19989000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
11675000
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
269816000
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
9816000
us-gaap Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax
ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
619000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
232625000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-19212000
us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
2715000
us-gaap Costs And Expenses
CostsAndExpenses
505309000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
41743000
us-gaap Share Based Compensation
ShareBasedCompensation
42638000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
37880000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1038000
us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
12152000
us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
2618000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
163547000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2765000
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci On Derivatives Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax
2000000
us-gaap Interest Expense
InterestExpense
2854000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
939000
us-gaap Cost Of Revenue
CostOfRevenue
71121000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
5368000
us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
335000
us-gaap Depreciation
Depreciation
27300000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
41698000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
7633000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
257468000
us-gaap Payments To Acquire Interest In Joint Venture
PaymentsToAcquireInterestInJointVenture
1258000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
54088000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
11362000
bmrn Depreciation Expense Capitalized Into Inventory
DepreciationExpenseCapitalizedIntoInventory
8221000
bmrn Intangible Asset Amortization And Contingent Consideration
IntangibleAssetAmortizationAndContingentConsideration
13173000
bmrn Stock Based Compensation Capitalized To Inventory
StockBasedCompensationCapitalizedToInventory
4200000
bmrn Percentage Of Product Revenue Exceeding Consolidated Net Product Revenue
PercentageOfProductRevenueExceedingConsolidatedNetProductRevenue
0.10 pure
bmrn Stockbased Compensation Capitalized
StockbasedCompensationCapitalized
4219000
bmrn Contingent Payments Upon Achievement Of Certain Regulatory And Licensing Milestones
ContingentPaymentsUponAchievementOfCertainRegulatoryAndLicensingMilestones
438400000
bmrn Supplemental Accounts Payable And Accrued Liabilities
SupplementalAccountsPayableAndAccruedLiabilities
7491000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
118810000 shares
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
5623000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
35111000 shares
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.52
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-968000
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
0
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
30676000
us-gaap Income Taxes Paid
IncomeTaxesPaid
5591000
us-gaap Investment Income Interest
InvestmentIncomeInterest
1819000
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
365540000
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-15000
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
0
us-gaap Excess Tax Benefit From Share Based Compensation Operating Activities
ExcessTaxBenefitFromShareBasedCompensationOperatingActivities
96000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
8154000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
276817000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
4846000
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-68184000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
12451000
us-gaap Maturities Of Subordinated Debt
MaturitiesOfSubordinatedDebt
0
us-gaap Interest Paid Net
InterestPaidNet
3597000
us-gaap Revenues
Revenues
368785000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-63889000
us-gaap Contracts Revenue
ContractsRevenue
1729000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
6905000
us-gaap Operating Income Loss
OperatingIncomeLoss
-63311000
us-gaap Royalty Revenue
RoyaltyRevenue
1516000
us-gaap Net Income Loss
NetIncomeLoss
-61335000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-3075000
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
535000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-9293000
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
0
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
-3325000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
165459000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-10610000
us-gaap Costs And Expenses
CostsAndExpenses
432096000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
272727000
us-gaap Share Based Compensation
ShareBasedCompensation
35414000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
33438000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
135058000
us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
0
us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
0
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
143124000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-6849000
us-gaap Interest Expense
InterestExpense
5709000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
235499000
us-gaap Impairment Of Intangible Assets Indefinitelived Excluding Goodwill
ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
6707000
us-gaap Cost Of Revenue
CostOfRevenue
65298000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
8625000
us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
96000
us-gaap Depreciation
Depreciation
25700000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
35907000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-143292000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
217855000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
37667000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
15825000
bmrn Depreciation Expense Capitalized Into Inventory
DepreciationExpenseCapitalizedIntoInventory
4744000
bmrn Intangible Asset Amortization And Contingent Consideration
IntangibleAssetAmortizationAndContingentConsideration
5819000
bmrn Stock Based Compensation Capitalized To Inventory
StockBasedCompensationCapitalizedToInventory
3000000
bmrn Stockbased Compensation Capitalized
StockbasedCompensationCapitalized
3042000
bmrn Supplemental Accounts Payable And Accrued Liabilities
SupplementalAccountsPayableAndAccruedLiabilities
1488000
CY2012 us-gaap Derivative Instruments Gain Loss Recognized In Other Comprehensive Income Effective Portion Net
DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet
-200000
CY2012 bmrn Number Of Customers Accounted For Largest Balance In Account Receivable
NumberOfCustomersAccountedForLargestBalanceInAccountReceivable
2 Customer
CY2012Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
123434000 shares
CY2012Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
35161000 shares
CY2012Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.04
CY2012Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-336000
CY2012Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
778000
CY2012Q3 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
126310000
CY2012Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
125000
CY2012Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-11761000
CY2012Q3 us-gaap Revenues
Revenues
128117000
CY2012Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7674000
CY2012Q3 us-gaap Contracts Revenue
ContractsRevenue
1210000
CY2012Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-10491000
CY2012Q3 us-gaap Royalty Revenue
RoyaltyRevenue
597000
CY2012Q3 us-gaap Net Income Loss
NetIncomeLoss
-5357000
CY2012Q3 us-gaap Costs And Expenses
CostsAndExpenses
138608000
CY2012Q3 us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
0
CY2012Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
46337000
CY2012Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-6404000
CY2012Q3 us-gaap Interest Expense
InterestExpense
1837000
CY2012Q3 us-gaap Cost Of Revenue
CostOfRevenue
24619000
CY2012Q3 us-gaap Depreciation
Depreciation
8900000
CY2012Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12139000
CY2012Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
66209000
CY2012Q3 bmrn Depreciation Expense Capitalized Into Inventory
DepreciationExpenseCapitalizedIntoInventory
2500000
CY2012Q3 bmrn Intangible Asset Amortization And Contingent Consideration
IntangibleAssetAmortizationAndContingentConsideration
1443000
CY2013Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
140796000 shares
CY2013Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
18986000 shares
CY2013Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.38
CY2013Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-147000
CY2013Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
574000
CY2013Q3 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
134330000
CY2013Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
239000
CY2013Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-52316000
CY2013Q3 us-gaap Revenues
Revenues
136874000
CY2013Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-43988000
CY2013Q3 us-gaap Contracts Revenue
ContractsRevenue
1754000
CY2013Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-50724000
CY2013Q3 us-gaap Royalty Revenue
RoyaltyRevenue
790000
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
-53020000
CY2013Q3 us-gaap Costs And Expenses
CostsAndExpenses
187598000
CY2013Q3 us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
1732000
CY2013Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
61841000
CY2013Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
704000
CY2013Q3 us-gaap Interest Expense
InterestExpense
526000
CY2013Q3 us-gaap Cost Of Revenue
CostOfRevenue
28054000
CY2013Q3 us-gaap Depreciation
Depreciation
9200000
CY2013Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
16205000
CY2013Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
88064000
CY2013Q3 bmrn Depreciation Expense Capitalized Into Inventory
DepreciationExpenseCapitalizedIntoInventory
2800000
CY2013Q3 bmrn Intangible Asset Amortization And Contingent Consideration
IntangibleAssetAmortizationAndContingentConsideration
9639000

Files In Submission

Name View Source Status
0001193125-13-413125-index-headers.html Edgar Link pending
0001193125-13-413125-index.html Edgar Link pending
0001193125-13-413125.txt Edgar Link pending
0001193125-13-413125-xbrl.zip Edgar Link pending
bmrn-20130930.xml Edgar Link completed
bmrn-20130930.xsd Edgar Link pending
bmrn-20130930_cal.xml Edgar Link unprocessable
bmrn-20130930_def.xml Edgar Link unprocessable
bmrn-20130930_lab.xml Edgar Link unprocessable
bmrn-20130930_pre.xml Edgar Link unprocessable
d594526d10q.htm Edgar Link pending
d594526dex311.htm Edgar Link pending
d594526dex312.htm Edgar Link pending
d594526dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending